This article also highlights the sensitivity of glioblastoma tumorspheres to BH3 mimetics targeting BCL-xL, suggesting that these drugs could be repurposed for glioblastoma treatment if the status of anti-apoptotic proteins is well characterized in patient samples. This evidence concerns the gene BCL2L1 and glioblastoma.